相关实验视频

Updated: May 22, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

托法西提尼布在早期活性轴性脊椎关节炎:随机双盲,安慰剂控制,多中心第四期研究的协议,FASTLANE

Valeria Rios Rodriguez¹, Lidia Sánchez-Riera², Hildrun Haibel³

¹Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Charité-Universitätsmedizin Berlin, Hindenburgdamm 30, Berlin 12203, Germany.

Therapeutic advances in musculoskeletal disease

|March 13, 2025

概括

这项研究评估了tofacitinib与安慰剂对早期轴性脊柱关节炎 (axSpA) 进行评估,这些患者的NSAID反应不足. 它评估了疗效和安全性,旨在改善这种疾病的治疗结果.

科学领域:

类风湿病学类风湿病学
免疫学免疫学免疫学
临床药理学临床药理学

背景情况:

早期开始治疗对于轴性脊柱关节炎 (axSpA) 的良好结果至关重要.
国际脊柱性关节炎协会 (ASAS) 的评估将早期 axSpA 定义为症状持续时间为2年或更短.
托法西提尼布是一种Janus激酶 (JAK) 抑制剂,已被批准用于结性脊髓炎治疗.

研究的目的:

为了比较托法西提尼布与安慰剂的疗效和安全性,在早期活跃axSpA.A.患者中比较托法西提尼布与安慰剂.
在对至少一种非类固醇抗炎药物 (NSAID) 反应不充分的患者中评估托法西提尼布.
评估早期 axSpA 患者接受 NSAID 背景治疗的治疗结果.

主要方法:

一个IV期,随机,双盲,安慰剂控制,多中心临床试验,涉及104名患者.
18-45岁的参与者具有活跃的早期axSpA (症状≤2年) 和客观的炎症迹象.
随机选择托法西提尼布5毫克每天两次或安慰剂,背景纳普洛森,16周.

主要成果:

主要终点:在第16周实现疾病缓解的患者比例 (ASDAS <1.3)
关键次要终点:第16周的MRISIJ骨质炎得分与基线的变化.
在治疗完成后长达4周的安全监测.

结论:

这项试验是第一个在ASAS定义的早期axSpA群体中研究JAK抑制剂的试验.
它旨在提供关于托法西提尼布在这个特定患者群体中的疗效和安全性概况的关键数据.
这些发现将为早期轴性脊柱关节炎的治疗策略提供信息.

关键词:

轴性脊椎关节炎轴性脊椎关节炎临床试验临床试验临床试验临床试验临床试验磁共振成像技术的使用托法西提尼布 (tofacitinib) 是一种治疗治疗治疗治疗治疗治疗

更多相关视频

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

相关概念视频

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...